VJHemOnc is committed to improving our service to you

ASCO 2020 | Magrolimab + azacitidine in MDS and AML

VJHemOnc is committed to improving our service to you

David Sallman

David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reviews the toleratbility and efficacy data reported from the phase 1b study of magrolimab, an anti-CD47 antibody, in combination with azacitidine in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter